{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lupus+Arthritis&page=2", "query": { "condition": "Lupus Arthritis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lupus+Arthritis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T20:16:03.464Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00341198", "title": "Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Autoimmune Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Environmental Health Sciences (NIEHS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 700, "start_date": "2002-04-02", "completion_date": "2006-12-12", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 3, "location_summary": "Iowa City, Iowa • Durham, North Carolina • Research Triangle Park, North Carolina", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Research Triangle Park", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00341198" }, { "nct_id": "NCT00594932", "title": "Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus", "Arthritis" ], "interventions": [ { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Oklahoma Medical Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "14 Years to 70 Years" }, "enrollment_count": 27, "start_date": "2006-11", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2020-10-09", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594932" }, { "nct_id": "NCT02429934", "title": "Abatacept for SLE Arthritis (IM101-330)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus Arthritis" ], "interventions": [ { "name": "abatacept also known as Orencia also known as CTLA4-Ig", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2015-10", "completion_date": "2019-09-01", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 2, "location_summary": "Los Angeles, California • San Diego, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02429934" }, { "nct_id": "NCT00000416", "title": "Prevention of Arthritis-Related Work Disability", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis", "Systemic Lupus Erythematosus", "Osteoarthritis, Knee", "Ankylosing Spondylitis" ], "interventions": [ { "name": "Rehabilitation counseling", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Boston University Charles River Campus", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 242, "start_date": "1997-09", "completion_date": "2001-08", "has_results": false, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000416" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" }, { "nct_id": "NCT03501667", "title": "Testing Pediatric Rheumatology Diagnostic Decision Support in Clinical Use", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)" ], "interventions": [ { "name": "Use of decision support tool", "type": "OTHER" }, { "name": "Use of UpToDate", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 900, "start_date": "2020-01-01", "completion_date": "2020-12-31", "has_results": false, "last_update_posted_date": "2020-07-07", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03501667" }, { "nct_id": "NCT04776161", "title": "Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatic Diseases", "Gout", "Adherence, Medication", "Lupus Erythematosus, Systemic" ], "interventions": [ { "name": "Cue-Reward Intervention", "type": "BEHAVIORAL" }, { "name": "Cue-Reward Intervention with possible intensification", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 62, "start_date": "2021-08-02", "completion_date": "2022-11-10", "has_results": true, "last_update_posted_date": "2023-10-04", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04776161" }, { "nct_id": "NCT06293365", "title": "Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sjögrens Disease", "Systemic Lupus Erythematosus", "Rheumatoid Arthritis" ], "interventions": [ { "name": "VAY736 1ml PFS", "type": "BIOLOGICAL" }, { "name": "VAY736 2 ml PFS", "type": "BIOLOGICAL" }, { "name": "VAY736 2ml AI", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 155, "start_date": "2024-07-02", "completion_date": "2029-01-16", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 17, "location_summary": "Anniston, Alabama • Fullerton, California • La Palma, California + 14 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "La Palma", "state": "California" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Lawrenceville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06293365" }, { "nct_id": "NCT03816345", "title": "Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autoimmune Disease", "Crohn Disease", "Dermatomyositis", "Hematopoietic and Lymphoid Cell Neoplasm", "Inflammatory Bowel Disease", "Malignant Solid Neoplasm", "Multiple Sclerosis", "Psoriasis", "Psoriatic Arthritis", "Rheumatoid Arthritis", "Sjogren Syndrome", "Systemic Lupus Erythematosus", "Systemic Scleroderma", "Ulcerative Colitis" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Fluoropyrimidine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Platinum Compound", "type": "DRUG" }, { "name": "Platinum Doublet", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2019-07-16", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816345" }, { "nct_id": "NCT03254784", "title": "A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Arthritic Psoriasis", "Psoriasis", "Inflammatory Bowel Diseases" ], "interventions": [ { "name": "BMS-986165 Capsule", "type": "DRUG" }, { "name": "BMS-986165 Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 49, "start_date": "2017-09-13", "completion_date": "2017-11-15", "has_results": false, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-06-26T20:16:03.464Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03254784" } ] }